Tam Anh General Hospital named international research site for RBS2418 | Healthcare Asia Magazine
, Vietnam
Photo from Tam Anh General Hospital Group via LinkedIn

Tam Anh General Hospital named international research site for RBS2418

The initiative will include local biomarker testing.

Vietnam’s Tam Anh General Hospital has been designated as the first international research site for RBS2418, an oral immunotherapy drug developed to activate the immune system in combating cancer.

The hospital’s involvement forms part of the VISTA-1 clinical trial, a collaborative effort with US experts.

The initiative will include local biomarker testing, ensuring Vietnamese patients receive care and treatments comparable to international protocols.

The new drug targets terminal cancer patients, particularly those with advanced colorectal cancer who have not responded to existing treatments.

Follow the link for more news on

Join Healthcare Asia Magazine community
Since you're here...

...there are many ways you can work with us to advertise your company and connect to your customers. Our team can help you dight and create an advertising campaign, in print and digital, on this website and in print magazine.

We can also organize a real life or digital event for you and find thought leader speakers as well as industry leaders, who could be your potential partners, to join the event. We also run some awards programmes which give you an opportunity to be recognized for your achievements during the year and you can join this as a participant or a sponsor.

Let us help you drive your business forward with a good partnership!